Clinical Scorecard: Via360 Expands Canal-Based MIGS Options
At a Glance
| Category | Detail |
|---|---|
| Condition | Open-Angle Glaucoma |
| Key Mechanisms | Combination of canaloplasty and trabeculotomy with controlled viscodilation. |
| Target Population | Patients with elevated intraocular pressure (IOP) and medication dependency. |
| Care Setting | Ophthalmic surgical settings. |
Key Highlights
- 510(k) clearance from the FDA for controlled viscoelastic delivery.
- Surgeon-controlled, on-demand viscoelastic delivery via ActiveInject technology.
- Microcatheter design allows advancement up to 360° within Schlemm’s canal.
- Effective for patients with pigment dispersion syndrome, pseudoexfoliation syndrome, and steroid response glaucoma.
- Reduces the need for filtering surgery in cases of significant IOP elevation.
Guideline-Based Recommendations
Diagnosis
- Consider MIGS for patients who may benefit from IOP reduction and reduced medication burden.
Management
- Utilize Via360 for maximum IOP lowering through combined canaloplasty and trabeculotomy.
Monitoring & Follow-up
- Monitor IOP and medication dependency post-procedure.
Risks
- Potential for catheter entering unintended areas, though tactile feedback aids in navigation.
Patient & Prescribing Data
Patients with open-angle glaucoma and elevated outflow resistance.
Significant reductions in IOP and topical medication burden observed.
Clinical Best Practices
- Employ ActiveInject technology for precise viscoelastic delivery.
- Utilize the rotatable cannula for access in complex anatomical cases.
- Streamline surgical prep with the Smart Prime feature to optimize viscoelastic volume.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.